Gilead-Yuhan’s co-promotion agreement for Sovaldi and Harvoni

Published: 2017-09-05 14:34:17

Updated: 2017-09-05 14:34:17

Gilead Sciences Korea(CEO Seung-Woo Lee) and Yuhan Corporation(CEO Jung-Hee Lee) announced a co-promotion ceremony of ‘Sovaldi’ and ‘Harvoni,’ chronic hepatitis C treatments, on the 31^st of August.

The co-promotion agreement is a strategic partnership to jointly sell and market the Gilead’s chronic hepatitis C treatments ‘Sovaldi’ and ‘Harvoni’ in Korea. Under the agreement, the two companies ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.